Artiva Biotherapeutics, Inc.
ARTV
$3.64
$0.061.68%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.29% | -4.64% | -26.19% | 7.88% | 2.08% |
| Total Depreciation and Amortization | 3.28% | 2.07% | 2.28% | -2.07% | 3.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.50% | -21.75% | 16.37% | -48.67% | -37.54% |
| Change in Net Operating Assets | 111.47% | -129.32% | -378.14% | -110.34% | 43,085.71% |
| Cash from Operations | 16.46% | -15.84% | -35.43% | -26.17% | 15.16% |
| Capital Expenditure | 43.13% | -106.46% | -698.44% | 33.33% | 79.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -23.89% | 111.57% | 1,262.08% | 99.31% | -7,299.78% |
| Cash from Investing | -22.93% | 111.83% | 1,132.19% | 99.26% | -9,783.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 3.03% | 0.00% | 0.00% | 13.16% | 51.28% |
| Issuance of Common Stock | -- | -100.00% | 500.00% | -99.99% | 756,777.27% |
| Repurchase of Common Stock | -166.67% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | 770.00% | 99.23% | -66.86% |
| Cash from Financing | 48.61% | -130.13% | 896.67% | -100.02% | 10,240.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -53.13% | 79.93% | 38.44% | -172.32% | 255.05% |